AR 12

Drug Profile

AR 12

Alternative Names: AR-12; NSC D728209; OSU-03012

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Acetate-CoA ligase inhibitors; Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; HSP70 heat shock protein inhibitors; HSP90 heat-shock protein inhibitors; Molecular chaperone GRP78 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryptococcosis; Tularaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Cryptococcosis; Onychomycosis; Tularaemia; Viral infections
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top